Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 533

Similar articles for PubMed (Select 18452412)

1.

Persistence with hepatitis C therapy in the Department of Veterans Affairs.

Iqbal SU, Cunningham F, Lee A, Miller DR, Li NC, Cheung R, Kazis L.

J Clin Pharm Ther. 2008 Jun;33(3):251-61. doi: 10.1111/j.1365-2710.2008.00912.x.

PMID:
18452412
2.

Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.

Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G.

J Interferon Cytokine Res. 2008 Oct;28(10):623-9. doi: 10.1089/jir.2007.0116.

PMID:
18778199
3.
4.

Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation.

Zopf S, Herold C, Hahn EG, Ganslmayer M.

Scand J Gastroenterol. 2009;44(4):486-90. doi: 10.1080/00365520802647400.

PMID:
19117241
5.

Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'.

Toyoda H, Kumada T.

Expert Opin Pharmacother. 2009 Dec;10(17):2845-57. doi: 10.1517/14656560903321521. Review.

PMID:
19891593
7.

Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin.

Brixner DI, Ye X, Chu TC, Blumentals WA, Hassanein TI.

Am J Health Syst Pharm. 2009 Dec 15;66(24):2171-8. doi: 10.2146/ajhp080711.

PMID:
19966085
10.

Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.

Sagir A, Heintges T, Akyazi Z, Oette M, Erhardt A, Häussinger D.

Liver Int. 2007 Sep;27(7):954-9.

PMID:
17696934
11.

Comparison of biochemical safety between PEG-IFN alpha-2a and PEG-IFN alpha-2b.

Katano Y, Kumada T, Nakano I, Toyoda H, Ishigami M, Hayashi K, Honda T, Goto H.

Hepatogastroenterology. 2009 Mar-Apr;56(90):485-91.

PMID:
19579626
12.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
13.

[Toxicity of the treatment of chronic hepatitis C with peginterferon alpha (2a or 2b) plus ribavirin in patients not previously treated].

Márquez Peiró JF, Valero Alcocer VE, Morales Suárez-Varela M, Llopis González A, Pérez Peiró C.

Med Clin (Barc). 2007 Nov 3;129(16):612-4. Spanish.

PMID:
18001672
14.

Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.

Yee HS, Currie SL, Tortorice K, Cozen M, Shen H, Chapman S, Cunningham F, Monto A.

Dig Dis Sci. 2011 Aug;56(8):2439-48. doi: 10.1007/s10620-011-1746-3. Epub 2011 Jun 2.

PMID:
21633833
15.

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M.

Infection. 2008 Jun;36(3):250-5. doi: 10.1007/s15010-007-7132-6. Epub 2008 May 3.

PMID:
18458815
16.

Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.

Foster GR.

Expert Opin Pharmacother. 2003 May;4(5):685-91. Review.

PMID:
12739994
17.

PEG-interferon in acute and chronic hepatitis C: a review.

Palumbo E.

Am J Ther. 2009 Nov-Dec;16(6):573-8. doi: 10.1097/MJT.0b013e3181960819. Review.

PMID:
19433975
18.

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, Bellón JM, Esteban H; GESIDA HIV/HCV cohort.

J Antimicrob Chemother. 2009 Jun;63(6):1256-63. doi: 10.1093/jac/dkp106. Epub 2009 Apr 10.

20.

Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.

Comai S, Cavalletto L, Chemello L, Bernardinello E, Ragazzi E, Costa CV, Bertazzo A.

Pharmacol Res. 2011 Jan;63(1):85-92. doi: 10.1016/j.phrs.2010.10.009. Epub 2010 Oct 19.

PMID:
20940053
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk